Arlington-based Abexxa Biologics Inc. has been acquired by a German pharmaceutical company. Boehringer Ingelheim plans to use Abexxa’s tech in targeting cancer-specific proteins located inside the cell to boost its tumor-antigen discovery and ways of targeting intracellular antigens. It could lead to new cancer immunotherapies that are effective in a broader range of patients. In 2016, Boehringer’s investment arm awarded Abexxa its initial investment funding. Abexxa then won its Ingelheim’s Innovation Prize later that year.
Error, group does not exist! Check your syntax! (ID: 6)
Arlington-based Abexxa Biologics Inc. has been acquired by a German pharmaceutical company. Boehringer Ingelheim
Share via:
[addtoany]
Error, group does not exist! Check your syntax! (ID: 7)
